[1] WHO/IFSC Task Force. Report of the 1995 WHO/ISFC task force on the definition and classification of cardiomyopathies[J]. Circulation, 1996, 93:841~842.
[2] Richie JL, Beteman TM, Bonow RO, et al. Guideline for clinical use of cardiac radionuclide imaging a report of the American College of Cardiology/American Heart Association Task force on assessment of diagnostic and therapeutic cardiovascular procedures (committee on radionuclide imaging)-developed in collaboration with American society of Nuclear Cardiology[J]. J Nucl Cardiol, 1995, 2:172~192.
[3] Weich HF, Strauss HW, Pitt B, et al. The extraction of thallium-201 by the myocardium[J]. Circulation, 1997, 56:188~191.
[4] Gerson MC. Cardiac Nuclear Medicine[M]. Third Edition, New York:McGraw-Hill, 1997. 689~711.
[5] Li LX, Nohara R, Okuda K, et al. Comparative study of 201Tl-scintigraphic image and myocardial pathologic finding in patients with dilated cardiomyopathy[J]. Ann Nucl Med, 1996, 10:307~314.
[6] Coimenares T, Alexanderson E, Varguez V, et al. Utility of perfusion SPECT study to differentiate between ischemic and nonischemic cardiomyopathy[J]. J Nucl Cardiol, 1999, 6:S3.
[7] Mody FV, Brunken RC, Stevenson LW, et al. Differentiating cardiomyopathy of coronary artery disease from nonischemic dilated cardiomyopathy utilization Positron Emission Tomography[J]. J Am Coll Cardiol, 1991, 17:373~383.
[8] Boffa GM, Zanco P, Valentina PO, et al. Positron emission tomography is a useful screeing tool in dilated cardiomyopath[J]. Eur Heart J, 1998, 19:Supplement V~Viii 642.
[9] Dicarli M F, Asgarzadie F, Schelbert F, et al. Quantitaive relation between myocardial viability and improvement in heart failure symptoms after revascularization in patients with ischemic cardiomyopathy[J]. Circulation, 1995, 92:3436~3444.
[10] Paglry PR, Beller GA, Watson DD, et al. Improved outcome after coronary bypass sugery in patients with ischemic cardiomyopathy and residual myocardial viability[J]. Circulation, 1997, 96:793~800.